Challenges of Protein Complex Analysis

For education only

This guide cannot diagnose a condition or recommend a personal treatment plan. Discuss medical questions with a qualified professional.

Protein complex analysis involves extensive interpretation of the structure and function of proteins, which are present in complex biological samples. Due to this, techniques like protein complex analysis have great value in understanding the complex organisms. Though recent protein complex analysis methods are efficient in identifying the structure and of protein complex, there are some limiting factors.

Credit: Lerner Vadim/ Shutterstock.com

Some of the factors that affect protein complex analysis are serum proteomics, the presence of membrane protein in proteome, complexity, etc. Much of the research is being performed to enhance the protein complex analysis process, which includes identifying whether the complexes are suitable for being modulated efficiently by small molecules. Some of the most common challenges that affect the protein complex analysis are discussed below.

Interference of protein–protein interactions

One of the main challenges faced during the protein complex analysis process is the development of compounds that interfere by acting on protein complexes.

In some cases like those involving ion channels (considered as the reliable target class earlier), the process of directing the compounds against individual proteins has not been possible whereas hist is implemented in many other cases. Simultaneously, several compounds have been identified, which act on alpha subunits involved in pore formation.

Some of those compounds are successfully implemented in clinical studies, which is mainly due to their critical side effects and lack of specificity. Many compounds that had been developed to act against individual proteins are now being implemented in acting against other targets.

Even at present, there exists a misconception that the interference of small molecules with protein–protein interactions is not possible, which is mainly due to the lack of understanding regarding the protein–protein interactions process. Protein interfaces have conformational flexibility in constitutive complex too. Moreover, studies involving allosteric proteins indicate that the ligands are responsible for structural changes that occur at protein–protein interfaces.

The binding sites of allosteric ligands are not restricted sterically, which is the advantage, and indicates that they are as efficient as traditional competitive agonist. Allosteric ligands are efficient in developing drugs that can act against protein complexes. The cell-based assays and high-content screening are the techniques involved in developing drugs against protein complexes.

Complexity challenge

The complexity challenge is another factor that affects the analysis of protein complexes. Two important strategies that are involved in resolving these challenges are recombinant approaches and those that are based on native sources.

Recombinant approaches, such as tagged protein co-purification analysis and yeast-two hybrid screens, consist of a systematic methodology that makes them reliable to resolve the complexity challenge. Both the aforementioned are based on gene expression from random libraries of yeast. Those methods prove to be inefficient when applied to proteome of simple organism. Half of the interactions are false-positive and interactions that involve membrane proteins are not detected.

Approaches that are based on native sources are based on both biochemical fractionation and mass-spectrometric identification. Some of the restrictions in these methods are complex source preparation methods and the amount of sample required.

The biochemical fractionation approach is an option for affinity purification based on a protein. Requirement of high affinity ligands is also a limiting factor in these approaches. High sensitivity and mass spectrometry reliability should be efficient as those in recent bioinformatics techniques. Aforementioned limitations restrict the large-scale application of these methods. Nevertheless, better results can be obtained if these approaches are carried out perfectly.

Presence of membrane proteins

Membrane proteins occupy over 30% of the entire complement of protein. Unfortunately, their tendency to get aggregated and get deposited in solid form in a solution restricts their analysis. Tryptic cleavage target residues such as arginine and lysine are not present in transmembrane segments, but are present only in the hydrophilic part of these membrane proteins.

Two-dimensional gel electrophoresis is not suitable for isolating these membrane proteins. These challenges can be overcome by various membrane solubilizing approaches that are used in resolving the solubility issues and in the analysis of fractions enriched in membranes.

In this method, solubilization is achieved through various processes, such as a fraction of an enriched yeast membrane is subjected to solubilization process in the existence of cyanogen bromide by adding 90% of formic acid solution; a microsomal membrane fraction is subjected to solubilization by boiling it in 0.5% of sodium dodecyl sulfate solution; and by using a sample of enriched membrane in thermal sonication and denaturation processes of proteins in 60% of methanol solution with trypsin. All the solubilization methods discussed earlier are efficient and used in optimization of membrane protein identification process.

Serum proteomics

Human serum contains about 10,000 types of proteins. The large variation in the serum concentration was a limiting factor for biomarker discovery. Human serum concentration contains a high amount of albumin when compared to other protein types but eliminating the albumin may also result in the elimination of other types of proteins such as peptide hormones, cytokines, etc. Various methods are currently used, which are efficient in identifying biomarkers discovered from serum. Some of the methods include 2D-PAGE analysis, SELDI-TOF MS, etc.

Sources:

Helpful context for this guide

Source-derived material selected through this article’s indexed topics.

Related questions

01With graph neural networks, foundation models, and diffusion models transforming the field, what can we predict reliably today that was difficult a decade ago and are there still any blind spots?

One major example is protein structure. Methods such as AlphaFold and Boltz-2 have transformed how we generate 3D structural data. Accurate protein structure prediction has been a decades-old challenge, and while there is still work to do on underrepresented protein classes, these models have opened an extraordinary pathway. We have also seen progress in multi-output models. Just over a decade ago (circa 2013), toxicology and property prediction models often focused on one endpoint at a time. Now, multi-output models, especially from methods such as graph neural networks (GNNs) and other deep learning methods, can predict multiple endpoints simultaneously. This allows for transfer learning between related properties. That creates opportunities across ADMET (absorption, distribution, metabolism, excretion, and toxicity) prediction and toxicology. Another exciting area is machine learning potentials. Molecular simulations traditionally rely on fixed mathematical functions to describe molecular interactions, but neural potentials can now replace or augment those functions. They can, in many cases, provide highly accurate simulations and structures at lower computational cost than quantum chemistry. However, its not just down to model architectures. The biggest blind spot behind all of these advances remains careful data curation, annotation, and collection. Open databases for example ChEMBL, PubChem and Chemspider together with data initiatives such as OpenADEMT and OpenBind to name but a few are making notable progress here. We still see some data for example on formulation chemistry often receiving less attention. Its is not just about data scale, but quality that is critical here to. Accessible high quality data sets are the fuel of AI methods. Architecture matters, but high-quality, accessible and abundant data is also absolutely critical.

Source: www.news-medical.net ↗

02Could we one day get rid of food allergies?

These seed epitopes are an exciting new addition to our understanding of oral tolerance. Scientists have already considered regulatory T cells as a promising immunotherapy route for people with severe food allergies. It may one day be possible to create regulatory T cells that are pre-programmed to tolerate certain foods and dampen immune responses to common allergens. "Diet is our most intimate interaction with our environment," says Blum. "Correctly recognizing foods as safe creates an anti-inflammatory environment to support nutrient acquisition and prevent allergy. Our research advances scientific understanding of the major dietary allergens, and points us toward future therapeutic interventions that could redirect allergic and autoimmune states." In the less-distant future, the researchers are excited to see their workflow for mapping proteins adapted to humans. The reagent they developed to track their proteins is now available for others to use, so they're hopeful that new insights into regulatory T cell-mediated oral tolerance are soon to come. Blum J. E., et al. (2026). Identification and characterization of dietary antigens in oral tolerance. Science Immunology. DOI: 10.1126/sciimmunol.aeb4684, https://www.science.org/doi/10.1126/sciimmunol.aeb4684.

Source: www.news-medical.net ↗

03What was done in this study?

In the study, published in Scientific Reports, the researchers built on their earlier discovery of the peptide called AC253. This compound was tested in mice with AD. It was found to block the attachment of beta-amyloid to a brain cell receptor called the amylin receptor, and thus inhibit its toxic effects, as shown by an improvement in spatial memory. However, it is difficult to administer this compound because it doesn’t cross the blood-brain barrier in large amounts, and is quickly broken down in the blood. The dosage must therefore be massively increased, pushing up the amounts required for efficacy and increasing the difficulty of administration, besides enhancing the chances of an immune reaction. One way out is to convert the formulation into a pill rather than an injectable form. The complex structure of AC253 makes this difficult as well. Instead, the team devised an ingenious solution. They cleaved the compound into smaller amylin peptides, or chains of 12-14 amino acids, and tested each for its anti-amyloid activity in old mice which showed signs of AD. In this way, they found two short peptides that had the same effects as the larger compound. In particular, the researchers identified a segment that was common to both peptides, namely, SQELHRLQTY.

Source: www.news-medical.net ↗

04What knowledge has your research provided, specifically regarding Alzheimer's disease?

The main protein or peptide in Alzheimer's disease patients is something called beta-amyloid. It has a 42 amino acid chain, and accumulates in the plaque between nerve cells in Alzheimer's disease patients. Beta-amyloid has been found to epimerize. Certain amino acids epimerize in the beta-amyloid at specific locations, and it turns out those amino acids are mainly aspartic acid and serine. There was no good way to analyze for such aberrations in beta-amyloid until now, and we have found a number of techniques that not only detect it, but can point out exactly where, within the beta-amyloid chain, the aberration is occurring and if there are more aberrations in Alzheimer's patients than in normal people. Image Credit:Shutterstock/Tavarius

Source: www.news-medical.net ↗

05What would be the impact on cancer patients if COTI-2 does prove to be effective in people with p53 mutant tumours?

Given the central role of p53 mutations in human cancers, COTI-2 could represent a breakthrough therapy for many cancer patients if clinical trials confirm its’ activity in people. If we consider a specific disease such as ovarian cancer, p53 mutations are found in more than 90% of these tumours. Preclinical animal experiments with a human ovarian cancer known to have a p53 mutation and be resistant to conventional chemotherapy demonstrated that treatment with COTI-2 as a single agent either completely halted tumour growth or lead to dramatic tumour regression depending on the dose. COTI-2 was associated with no observable toxicity in these experiments.

Source: www.news-medical.net ↗

About the author

Peptide Therapy Guide Editorial Team

Editorial team for Peptide Therapy Guide.

View all articles →

Interference of protein–protein interactions

Complexity challenge

Presence of membrane proteins

Serum proteomics

Sources:

Further Reading

Related questions

Peptide Therapy Guide Editorial Team

Study unveils protein complex critical for sperm morphology

What are Introns and Exons?

Protein Microarray Applications

Novel peptide PEPITEM shows promise in fighting 'inflammaging'